The American Journal of Medicine
Volume 123, Issue 6 , Pages 536-541, June 2010

Adherence to Pharmacological Thromboprophylaxis Orders in Hospitalized Patients

  • John Fanikos, RPh, MBA

      Affiliations

    • Department of Pharmacy, Brigham and Women's Hospital, Boston, Mass
  • ,
  • Leslie Ann Stevens, BS

      Affiliations

    • Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Mass
  • ,
  • Matthew Labreche

      Affiliations

    • Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Mass
  • ,
  • Gregory Piazza, MD

      Affiliations

    • Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Mass
  • ,
  • Elaine Catapane, MEd, MT (ASCP)

      Affiliations

    • Harvard Clinical Research Institute, Harvard Medical School, Boston, Mass
  • ,
  • Lena Novack, PhD

      Affiliations

    • Harvard Clinical Research Institute, Harvard Medical School, Boston, Mass
  • ,
  • Samuel Z. Goldhaber, MD

      Affiliations

    • Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Mass
    • Corresponding Author InformationRequests for reprints should be addressed to Samuel Z. Goldhaber, MD, Cardiovascular Division, Brigham and Women's Hospital, 75 Francis Street, Boston, MA 02115

Abstract 

Objective

We compared adherence to unfractionated heparin (UFH) 2 or 3 times daily prophylaxis orders versus low-molecular-weight heparin (LMWH) once daily orders. Our goals were to determine which strategy demonstrated the best adherence in terms of timing and frequency of dose administration, and to determine reasons for ordered heparin not being administered.

Methods

We queried our electronic medication administration record where nurses document reasons for delayed administration or omitted doses. We identified 250 consecutive patients who were prescribed prophylaxis with UFH 2 or 3 times daily or LMWH once daily. We followed patients for their hospitalization to determine adherence to physicians' prophylaxis orders.

Results

Adherence, defined as the ratio of prophylaxis doses given to doses ordered, was greater with LMWH (94.9%) than UFH 3 times daily (87.8%) or UFH twice daily (86.8%) regimens (P <.001). Patients receiving LMWH more often received all of their scheduled prophylaxis doses (77%) versus UFH 3 times daily (54%) or UFH twice daily (45%) (P <.001). There were no differences between regimens regarding reasons for omitted doses. The most common reason for late or omitted doses was patient refusal, which explained 44% of the UFH and 39% of the LMWH orders that were not administered.

Conclusions

LMWH once a day had better adherence than UFH 2 or 3 times daily. For both LMWH and UFH, patient refusal was the most common reason for not administering prophylaxis as prescribed. These findings require consideration when evaluating pharmacological prophylaxis strategies. Educational programs, explaining the rationale, may motivate patients to improve adherence during hospitalization.

Keywords: Low-molecular-weight heparin, Medication adherence, Prophylaxis, Unfractionated heparin, Venous thromboembolism

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 30.00 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 Funding: Sanofi-aventis.

 Conflict of Interest: John Fanikos, RPh, MBA serves on the Speakers Bureau for sanofi-aventis and GlaxoSmithKline and has served as a consultant/advisory board participant. Samuel Z. Goldhaber, MD, receives research funds and is a consultant for sanofi-aventis, Eisai, Bristol-Myers Squibb, and Boehringer-Ingelheim. The remaining authors have no conflicts to disclose.

 Authorship: All authors had access to the data and participated in the manuscript preparation.

PII: S0002-9343(10)00066-5

doi:10.1016/j.amjmed.2009.11.017

The American Journal of Medicine
Volume 123, Issue 6 , Pages 536-541, June 2010